A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001

Journal of Experimental and Clinical Cancer Research

Volumn 23, Issue 3, 2004, Pages 447-454

  Alymara, V ^a   Tzouvara, E ^a   Vartholomatos, G ^a   Chaidos, A ^a   Tsiara, St ^a   Bourantas, K L ^a,b  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b Dept of Int Med and Hematology ^*  (Greece)

Author keywords

AML; Elderly; Intensive chemotherapy

Indexed keywords

CYTARABINE; ERYTHROPOIETIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALOPECIA; ARTICLE; BLEEDING DISORDER; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONSTIPATION; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; EDEMA; EPISTAXIS; ERYTHROLEUKEMIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HUMAN; INFECTION; LEUKEMIA REMISSION; LIVER DISEASE; MALE; MYELODYSPLASIA; PETECHIA; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; PURPURA; RELAPSE; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTHEMIA; TREATMENT OUTCOME; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; ETOPOSIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IDARUBICIN; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TRETINOIN;

EID: 8644290064     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Rowe J.M.: Acute Leukemia Forum'98: advances and controvercies in the biology and treatment of acute myelogenous leukemia and myelodysplasia: introduction. Leukemia 12 (Suppl. 1), 1998.
2. Lowenberg B., Downing J.R., Burnett A.: Acute myeloid leukemia (review). New Engl. J. Med. 106:851-859, 1999.
3. Baudard M., Beauchamp-Nicoud A., Delmer A., Rio B., Blanc C.M., Zittoun R., Marie J.P.: Has prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16-year period. Leukemia 13: 1481-1490, 1999.
4. Johnson P.R., Yin J.A.: Prognostic factors in elderly patients with acute myeloid leukemia. Leuk. Lymph. 16: 51, 1994.
5. Leith C.P., Kopechy K.J., Chen I.M. et al.: Frequency and clinical significance of the expression of the multidrug recistance proteins MDR-1/P-glucoprotein, MRP1 and LPR in acute myeloid leukemia. A Southwest Oncology Group study. Blood 94:1086-1099, 1999.
6. Leith C., Kopechy K.J., Willman C.L. et al.: Acute myeloid leukemia in the elderly: high frequency of trilineage dyspoiesis suggests that elderly AML is biochemically similar to AML arising secondary to myelodysplasia [abstract}. Blood 88:559a, 1996.
7. Rowe J.M.: Treatment of acute myelogenous leukemia in older adults. Leukemia 14: 480-487, 2000.
8. Lowenberg B.: Managing therapy in older adult patients with acute myeloid leukaemia. Semin. Hematol. 38: 10-16, 2001.
9. DeLima M., Ghaddar H., Pierce S., Estey E.: Treatment of newly-diagnosed acute myelogenous leukemia in patients aged 80 years and above. Br. J. Haematol. 93: 89-95, 1996.
10. Hamplin T.J.: Disappointments in treating acute leukemia in the elderly. New Engl. J. Med. 25: 1712-1713, 1995.
11. Sekeres M.A., Stone R.M.: The challenge of acute myeloid leukaemia in older patients. Curr. Opin. Oncol. 14(1): 24-30, 2002.
12. Lowenberg B., Susieu S., Archimbaud E., Haak H., Stryckmans P., deCataldo R., Detter A.W., Berneman Z.N., Thycca A., van der Lelie J., Sonneveld P., Vissani G., Fillet G., Hayat M., Hagemeijer A., Solbu G,. Zittoun R.: Mitoxantrone versus daunorubicin in induction and consolidation therapy: the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report of the Leukemia Organisation for the Research and Treatment of Cancer and the Dutch-Belgium Hemato-Oncology Cooperative Hovon Group randomized phase III study AML-9. J. Clin. Oncol. 16: 872-880, 1998.
13. Wiernik P.H., Banks P.L.C., Case D.C., Arlin Z.A., Periman P.O., Todd M.B., Ritch T.S., Ench R.E., Weitberg A.B.: Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 79:313-319, 1992.
14. Pignon B., Witz F., Harousseau J.L.: On behalf of the Goelam group. Treatment of acute myelogenous leukemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. Br. J. Heamatol. 94:333-341, 1996.
15. The AML Collaborative Group. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclins) as induction therapy for acute myeloid leukemia. Br. J. Heamatol. 103: 100-109, 1998.
16. Bishop J.F., Lowenthal R.M., Joshua D., Matthews J.P., Todd D., Cobcroft R., Whiteside M.G., Kronenberg H., Ma D., Dodds A., Herrmann R., Szer J., Wolf M.M., Young G.A.: Etoposide in acute nonlymphocytic leukemia. Blood 75: 27-32, 1990
17. Ho A.D., Brado B., Haas R., Hustein W.: Etoposide in acute leukemia: past experience and future prospectives. Cancer 67, 281-284, 1991.
18. Adamson J.W., Finch C.A.: Erythropoietin and the regulation of erythropoiesis in diGuglielmo's syndrome. Blood 36:590, 1970.
19. Mitjavila F.M., Villeval J.L., Cramer P.: Effects of Granulocyte- Macrophage Colony- Stimulating Factor and erythropoietin on leukemic colony formation in human early erythroblastic leukemias. Blood 70: 965, 1987.
20. Camera A., Volpicelli M., Villa M.R., et al.: Complete remission induced by high-dose erythropoietin and granulocyte colony-stimulating factor in acute myeloid erythroleukemia (AML-M6 with maturation). Hematologica 87: 1225-1227, 2002.
21. Miyazaki E., Kohgo Y., Hirayama M., Kawanishi J., Kato J. et al.: Remission after erythropoietin administration for erythroleukemia: a case study. Blood 82:1378-1380, 1993.
22. Tallman M.S., Andersen J.K., Schiffer C.A., Appelbaum F.R., Feusner J.H., Ogden A., Shepherd L., Willman C., Bloomfield C.D., Rowe J.M., Wiernic P.H.: All transretinoic acid in acute promyelocytic leukemia. New Engl. J. Med. 337: 1021-1028, 1997.
23. Gancer A., Heil G.: Use of hematopoietic growth factors in the treatment of acute myelogenous leukemia. Curr. Opin. Hematol. 4: 191, 1997.
24. Heil G., Hoelzer D., Sanz M.A., Lechner K., Liu Yin J.A., Papa G., Noens L., Szer J., Ganser A., O'Brien C., Matcham J.: A randomized, double-blind, placebo-controled, phase III study of Filgrastin in remission induction and consolidation therapy for adults with de novo acute myeloid leukaemia. Blood 90:4710-4718, 1997.
25. The AML Cooperative Study Group. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukaemia. New Engl. J. Med. 332:1678-1683, 1995.
26. The Cancer and Leukemia Group B. Granulocyte-Macrophage colony- stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukaemia. New Engl. J. Med. 332:1671-1677, 1995.
27. The Cancer and Leukemia Group B. Intensive post remission chemotherapy in adults with acute myeloid leukaemia. New Engl. J. Med. 331:896-903, 1994.
28. Stone R.M.: Post remission therapy in adults with acute myeloid leukaemia. Semin. Hematol. 38:17-23, 2001.
29. Cassileth P.A., Lynch E., Hines J.D., et al.: Varying intensity of post remission therapy acute myeloid leukaemia. Blood 79:1924-1930, 1992.
30. Rule S., Poirer V, Singer C.: Management of acute myeloid leukaemia. A regional audit in the south and west of the United Kingdom. Clin. Med. 1(4):313-316, 2001.
31. Goldstone A.H., Burnett A.K., Wheatley K., Smith A.G., Hutchinson R.M., Clark R.E., Medical Research Council Adult Leukemia Working Party: Attempts to improve treatment outcomes in acute myeloid leukaemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML II trial. Blood 98, 1302-1311, 2001.
32. Pinto A., Zagonel V., Ferrara F.: Acute myeloid leukaemia in the elderly: biology and therapeutic strategies. Crit. Rev. Oncol. Hematol. 39: 275-87, 2001.
33. Johnson P.R.E., Hunt L.P., Yin J.A.L.: Prognostic factors in elderly patients with acute myeloid leukemia: development of a model to predict survival. Br. J. Hematol. 85: 300-306, 1993.
34. Veneri D., Zanetti F., Franchini M., Ambrosetti A., Pizzolo G.: Acute myeloid leukemia in the elderly: evaluation of overall survival in 69 consecutive patients. Heamatologica 4: 447, 2002.
35. Baudard M., Marie J.P., Cadiou M., Viquie F., Zittoun R.: Acute myelogenous leukemia in the elderly: retrospective study of 235 consecutive patients. Br. J. Heamatol. 86: 82-91, 1994.
36. Hiddemann W., Kern W., Schoch C. et al.: Management of acute myeloid leukemia in elderly patients. J. Clin. Oncol. 17: 1569-3576, 1999.
37. Bennett J.M., Young M.L., Adersen J. et al.: Long-term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group experience. Cancer Supplement 80: 2205-2209, 1995.